New Drug Targets Bone Disease That Causes Hearing Loss
The drug LGK974, which inhibits the Wnt signaling pathway, shows promise in reversing excessive bone growth in sclerosteosis.
The drug LGK974, which inhibits the Wnt signaling pathway, shows promise in reversing excessive bone growth in sclerosteosis.
Sound Pharmaceuticals' Phase 3 trial of an anti-inflammatory drug for Meniere’s disease showed significant improvements in hearing loss.
Amptify introduced a new curriculum that is designed to support individuals with unique auditory challenges.
When a COVID-19 survivor reports that they have been diagnosed with brain fog or mild cognitive impairment (BF/MCI), or these terms appear in a medical report, hearing care professionals should be aware that many of the BF/MCI symptoms are very similar to those seen in patients with (central) auditory processing disorder. This article by audiologist Robert DiSogra, AuD, reviews the research on this subject and provides recommendations.
In an article published on the ”Discover Magazine” website, author Sarah Katz challenges the view in the scientific community that deafness is a problem that needs to be cured, potentially by new CRISPR technology that could eliminate a TMC1 gene mutation.
A team of Mass Eye and Ear researchers in the Eaton-Peabody Laboratories have been awarded a five-year, $12.5 million P50 Clinical Research Center Grant from the National Institute on Deafness and Other Communicable Disorders (NIDCD) of the National Institutes of Health (NIH) to continue their research on cochlear synaptopathy, or hidden hearing loss, a type of hearing damage first discovered at Mass Eye and Ear in 2009.
A new product designed to treat eardrum perforations developed by a Harvard doctoral student, Nicole Black, has just won the “Cure It!” Lemelson-MIT Student Prize.